Biosimilar Awareness, Access and Savings Continue to Grow - a podcast by Unknown

“As biosimilars receive FDA approval and more and more become available to patients, we're beginning to see a greater understanding and appreciation for these medicines as lower cost options,” explains Dr. Hillel Cohen, executive director of scientific affairs in the Sandoz division of Novartis and Sandoz representative to the education committee of the US Biosimilars Council. “You are not being switched to a new medication. You're being kept on the same medication that's being made by a different manufacturer.”

Further episodes of DIA: Driving Insights to Action

Further podcasts by Unknown

Website of Unknown